Abeona Therapeutics Inc (NASDAQ:ABEO)‘s stock had its “buy” rating reaffirmed by research analysts at Jefferies Group LLC in a research note issued on Friday. They presently have a $11.00 target price on the biopharmaceutical company’s stock. Jefferies Group LLC’s price objective suggests a potential upside of 117.82% from the company’s previous close.
Other research analysts have also issued reports about the stock. HC Wainwright set a $20.00 target price on shares of Abeona Therapeutics and gave the company a “buy” rating in a research note on Monday, February 6th. Rodman & Renshaw reiterated a “buy” rating and issued a $20.00 target price (up from $17.00) on shares of Abeona Therapeutics in a research note on Tuesday, February 7th. Zacks Investment Research upgraded shares of Abeona Therapeutics from a “hold” rating to a “buy” rating and set a $5.25 target price on the stock in a research note on Tuesday, January 31st. Maxim Group set a $14.00 target price on shares of Abeona Therapeutics and gave the company a “buy” rating in a research note on Wednesday, January 18th. Finally, Cantor Fitzgerald set a $21.00 target price on shares of Abeona Therapeutics and gave the company a “buy” rating in a research note on Monday, December 12th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $15.18.
Abeona Therapeutics (NASDAQ:ABEO) remained flat at $5.05 during midday trading on Friday. The stock had a trading volume of 190,008 shares. The company’s market capitalization is $201.79 million. Abeona Therapeutics has a one year low of $2.27 and a one year high of $9.44. The firm has a 50 day moving average of $5.18 and a 200 day moving average of $5.70.
Your IP Address:
A number of hedge funds have recently bought and sold shares of the company. Knoll Capital Management LP bought a new stake in Abeona Therapeutics during the third quarter valued at about $8,036,000. Perceptive Advisors LLC acquired a new stake in shares of Abeona Therapeutics during the fourth quarter valued at $4,085,000. Kavi Asset Management LP raised its stake in shares of Abeona Therapeutics by 477.6% in the fourth quarter. Kavi Asset Management LP now owns 365,600 shares of the biopharmaceutical company’s stock valued at $1,773,000 after buying an additional 302,300 shares during the period. Opaleye Management Inc. raised its stake in shares of Abeona Therapeutics by 300.0% in the fourth quarter. Opaleye Management Inc. now owns 400,000 shares of the biopharmaceutical company’s stock valued at $1,940,000 after buying an additional 300,000 shares during the period. Finally, Highbridge Capital Management LLC acquired a new stake in shares of Abeona Therapeutics during the third quarter valued at $1,591,000. Institutional investors own 17.79% of the company’s stock.
About Abeona Therapeutics
Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.
This story was originally published by WKRB News (http://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://www.wkrb13.com/markets/1990843/jefferies-group-llc-reaffirms-hold-rating-for-abeona-therapeutics-inc-abeo.html
Receive News & Ratings for Abeona Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.